Steve Schonfeld’s BioAge Labs BIOA Stock Holding History

Steve Schonfeld’s Portfolio BIOA Stock Details BIOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-51,366	Closed	-$680K	–	2767
2025 Q4	$680K	Buy	+51,366	New	+$455K	﹤0.01%	1271

Other funds holding BIOA

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Steve Schonfeld's BIOA Position: Q1 2026 in Review

Steve Schonfeld sold out of BioAge Labs (BIOA) in Q1 2026, closing a stake of 51,366 shares — an estimated $680K sold.

Steve Schonfeld first reported a position in BIOA in Q4 2025 and held it in 1 quarter. The position peaked at $680K in Q4 2025. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

Steve Schonfeld reported no remaining BioAge Labs position as of Q1 2026 after selling out during the quarter.
Steve Schonfeld sold 51,366 BioAge Labs shares in Q1 2026, an estimated $680K.
Steve Schonfeld first reported a position in BioAge Labs in Q4 2025 and held it in 1 quarter.
Steve Schonfeld's BioAge Labs position peaked at $680K in Q4 2025.
144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.